StreetInsider.com News Articles

Form 8-K LeonaBio, Inc. For: Aug 26

Wed, 26 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260826/26981577.html

Form 8-K LeonaBio, Inc. For: Aug 26

Wed, 26 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260826/26981577.html

Form SCHEDULE 13D/A LeonaBio, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Tue, 25 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260825/26974561.html

Form SCHEDULE 13D/A LeonaBio, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Tue, 25 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260825/26974561.html

Form SCHEDULE 13G/A LeonaBio, Inc. Filed by: ACORN BIOVENTURES, L.P.

Thu, 20 Aug 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260820/26954443.html

Form SCHEDULE 13G/A LeonaBio, Inc. Filed by: ACORN BIOVENTURES, L.P.

Thu, 20 Aug 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260820/26954443.html

LeonaBio (LONA) PT Lowered to $15 at Mizuho

Wed, 19 Aug 2026 06:40:50 -0400

(Updated - August 19, 2026 6:40 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on LeonaBio (NASDAQ: LONA) to $15.00 (from $16.00) while maintaining a Outperform rating.

The analyst commented: "LONA reported 2Q26 results via press release late last Friday (8/14), with little in the way of meaningful updates. We caught up with management yesterday, and most importantly, LONA's Phase 3 ELAINE-3 study for lead asset lasofoxifene/laso (a selective estrogen receptor modulator/SERM) in treatment-resistant ER+/HER2- ESR1-mutant metastatic breast cancer/BrCa continues to advance, with key milestones (trial enrollment completion in 4Q26, and top-line data in 2H27) still on track. We also

LeonaBio (LONA) PT Lowered to $15 at Mizuho

Wed, 19 Aug 2026 06:40:50 -0400

(Updated - August 19, 2026 6:40 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on LeonaBio (NASDAQ: LONA) to $15.00 (from $16.00) while maintaining a Outperform rating.

LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c

Mon, 17 Aug 2026 06:13:12 -0400

LeonaBio, Inc. (NASDAQ: LONA) reported Q2 EPS of ($0.80), $0.32 better than the analyst estimate of ($1.12).

For earnings history and earnings-related data on LeonaBio, Inc. (LONA) click here.

LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development

Mon, 17 Aug 2026 04:41:23 -0400

Citizens analyst Jason Butler reduced the price target on LeonaBio (NASDAQ: LONA) to $17.00 [from $18) and reiterated a Market Outperform rating.

The analyst commented, "Continuing to advance pipeline development; we reiterate our Market Outperform rating though decrease our risk-adjusted, DCF-derived price target to $17 from $18 on LeonaBio. LeonaBio reported 2Q26 financial results and business updates, reiterating timelines for top-line results from the ongoing Phase 3 ELAINE-3 trial in 2H27. The trial is on track to complete enrollment in 4Q26 and the company is actively engaged in commercial readiness activities, including CMC and regulatory preparations. LeonaBio ended 2Q26 with

Form 10-Q LeonaBio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930671.html

Form 10-Q LeonaBio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930671.html

Form 8-K LeonaBio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930466.html

Form 8-K LeonaBio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930466.html

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

Fri, 14 Aug 2026 16:05:00 -0400

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

BOTHELL, Wash., Aug. 14, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2026, and provided recent pipeline and business updates.

“We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

Fri, 14 Aug 2026 16:05:00 -0400

“We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3

LeonaBio to present lasofoxifene data at breast cancer summit

Wed, 12 Aug 2026 07:01:20 -0400

LeonaBio, Inc. (NASDAQ: LONA) announced that its lead drug candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's 4th Summit on Breast Cancer, scheduled for August 18-22, 2026, in Kona, Hawaii.

Jessica Tao, M.D., a medical oncologist at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, is scheduled to present on lasofoxifene and the Phase 3 ELAINE-3 clinical trial on August 19, 2026. The trial is evaluating lasofoxifene in combination with abemaciclib for the treatment of ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

David Portman, M.D., Founder and Chief Executive Officer of Sermonix and a consultant to LeonaBio, will lead an industry

LeonaBio to present lasofoxifene data at breast cancer summit

Wed, 12 Aug 2026 07:01:20 -0400

David Portman, M.D., Founder and Chief Executive Officer of Sermonix and a consultant to LeonaBio, will lead an industry

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

Wed, 12 Aug 2026 07:00:00 -0400

On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027

BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology’s 4th Summit on Breast Cancer taking place from August 18-22, 2026, in Kona, Hawaii.

“We are honored to share the body of clinical and scientific evidence supporting lasofoxifene

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

Wed, 12 Aug 2026 07:00:00 -0400

On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027

“We are honored to share the body of clinical and scientific evidence supporting lasofoxifene

Citizens Upgrades LeonaBio (LONA) to Market Outperform

Thu, 30 Jul 2026 03:03:56 -0400

Citizens analyst Jason Butler upgraded LeonaBio (NASDAQ: LONA) from Market Perform to Market Outperform with a price target of $18.00.

The analyst comments: “Lasofoxifene represents an attractive novel treatment option in ESR1 ER +/HER2- advanced breast cancer with Phase 3 results ~12 months away; we upgrade our rating on LeonaBio (formerly Athira) from Market Perform to Market Outperform and introduce an $18 risk-adjusted, DCF-derived price target. LeonaBio exclusively licensed lasofoxifene, a selective estrogen receptor modulator (SERM), from Sermonix Pharmaceuticals (private) in December 2025, and is well funded to execute the ongoing Phase 3 ELAINE-3 trial, with results expected in 2H27. The

Citizens Upgrades LeonaBio (LONA) to Market Outperform

Thu, 30 Jul 2026 03:03:56 -0400

Citizens analyst Jason Butler upgraded LeonaBio (NASDAQ: LONA) from Market Perform to Market Outperform with a price target of $18.00.

Citizens Upgrades LeonaBio (LONA) to Market Outperform

Thu, 30 Jul 2026 03:03:55 -0400

Citizens analyst Jason Butler upgraded LeonaBio (NASDAQ: LONA) from Market Perform to Market Outperform with a price target of $18.00.

Citizens Upgrades LeonaBio (LONA) to Market Outperform

Thu, 30 Jul 2026 03:03:55 -0400

Citizens analyst Jason Butler upgraded LeonaBio (NASDAQ: LONA) from Market Perform to Market Outperform with a price target of $18.00.

LeonaBio presents ALS drug at development summit, plans phase 2 trial

Thu, 04 Jun 2026 07:01:08 -0400

LeonaBio Inc. (NASDAQ: LONA) announced that its Chief Medical Officer Javier San Martin presented data on the company's experimental ALS treatment at the 5th Annual ALS Drug Development Summit in Boston. The presentation covered the clinical development program for brelgometon, previously known as ATH-1105.

The company disclosed that brelgometon has received the International Nonproprietary Name designation from health authorities. The drug candidate is an oral treatment designed to modulate the neurotrophic HGF system and penetrate the brain barrier.

LeonaBio plans to initiate a Phase 2 proof-of-concept study in the second half of 2026. The randomized, double-blind, placebo-controlled trial will evaluate brelgometon's efficacy,